This website is for US healthcare professionals


Log In to Bolder Science


Don't have an account? Sign Up


Please enter your email address.

You will receive a link to create a new password via email.

Log In


Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Vasopressin Injection Versus Misoprostol During Hysteroscopic Myomectomy In Reducing Blood Loss And Operation Time.

  • identifier


  • Recruitment Status


  • First Posted

    April 29, 2019

  • Last update posted

    April 29, 2019

Study Description

Brief summary:

A prospective randomized study designed to compare the efficacy of transcervical vasopressin injection versus vaginal misoprostol in reducing intra -operative blood loss during hysteroscopic mymectomy .

  • Condition or Disease:Submucous Leiomyoma of Uterus
  • Intervention/Treatment: Drug: Misoprostol
    Drug: Vasopressin
  • Phase: Phase 2/Phase 3

Detailed Description

This was a prospective, randomized, study on forty women with symptomatic submucous myoma presented mostly with bleeding and/or infertility scheduled for hysteroscopic myomectomy were randomized to groups (group A) 20 patients transcervical intramyoma vasopressin injection and (group B) 20patients with vaginal misoprostol is used .

Study Design

  • Study Type: Interventional
  • Actual Enrollment: 40 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Single (Participant)
  • Primary Purpose: Treatment
  • Official Title: Efficacy of Transcervical Vasopressin Injection VersusVaginal Misoprostol During Hysteroscopic Myomectomy in Reducing Operative Blood Loss and Operation Time: A Randomized Trial.
  • Actual Study Start Date: May 2016
  • Actual Primary Completion Date: January 2017
  • Actual Study Completion Date: March 2017

Arms and interventions

Arm Intervention/treatment
Active Comparator: misoprostol group
20 cases received 400 microgram prostaglandin E1 analogue, misoprostol, (Misotac®, 200 microgram, by SIGMA pharmaceutical industries, Alexandria, Egypt), intra-vaginally, 2 hr before operation.
Drug: Misoprostol
prostaglandin E1 analogue vaginally inserted two hours before hystertsopic myomectomy to evaluate intraoperative blood loss and operative time needed for completion of myomectomy
Active Comparator: vasopressin group
20 patients who had hysteroscopic guided intralesional vasopressin injection before hysteroscopic myomectomy
Drug: Vasopressin
one ampoule of vasopressin was diluted to 50 ml of normal saline, and 10 ml (4 units of vasopressin) was withdrawn in a syringe. Needle was inserted through the working channel of the hysteroscope until its tip was seen. The needle tip was pointed to the site of injection under hysteroscopic guidance during the whole injection technique. Aspiration was done first to avoid intravascular injection of vasopressin. The diluted solution was injected into the surface, especially to parts with dilated vasculature till they blanch.

Outcome Measures

  • Primary Outcome Measures: 1. intraoperative bleeding [ Time Frame: start with the first resectoscope myoma cut till withdrawal of hysterscope through the cervix at the end of the procedure ]
    subjective assessment of bleeding by the surgeon.
  • 2. operative time [ Time Frame: start with insertion of hysterscope through the cervix ends with withdrawal of hysterscopy through the cervix at the end of the procedure ]
    time needed for completion of myomectomy procedure
  • 3. haemoglobin and hematocrit deficit [ Time Frame: 24 hours before myomectomy and 24 hour after myomectomy ]
    haemoglobin and hematocrit values before and after myomectomy
  • Secondary Outcome Measures: 1. Degree of visual clarity [ Time Frame: start with the first resectoscope myoma cut till the completion of myoma resection ]
    visual analogue scale straight horizontal line of fixed length, usually 100 mm and the ends are defined as the extreme limits of the parameter)
  • 2. Fluid deficit [ Time Frame: start with insertion of hysterscope through the cervix ends with withdrawal of hysterscopy through the cervix at the end pf the procedure ]
    calculation the fluid deficit between in flow volume and outflow volume
  • 3. time need for cervical dilatation [ Time Frame: start from grasping the cervix till insertion of hysterescope ]
    time needed to dilate the cervix to admit the operative hysterescope

Eligibility Criteria

  • Ages Eligible for Study: 18 to 40 Years (Adult)
  • Sexes Eligible for Study: Female
  • Accepts Healthy Volunteers: No


Inclusion Criteria:

- symptomatic women presented with bleeding or infertility and scheduled for
hysterscopic myomectomy

- grade 0 and grade 1 submucous myomas

- less than 5 centimeters in diameter

Exclusion Criteria:

- Patients with grade 2 submucous myoma or more

- patients with submucous myomas larger than 5 cm in diameter

- postmenopausal women

- patients received GnRh analogue in last 6 months

- patients with anticoagulant therapy

- patients with endometrial premalignant or malignant pathologies

- patients with cardiovascular diseases, asthma or impaired kidney functions

Contacts and Locations



Sponsors and Collaborators

Zagazig University

More Information

  • Responsible Party: Zagazig University
  • Identifier: NCT03930069 History of Changes
  • Other Study ID Numbers: Hysterscopioc myomectomy
  • First Posted: April 29, 2019 Key Record Dates
  • Last Update Posted: April 29, 2019
  • Last Verified: April 2019
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Leiomyoma Myofibroma